1. All Products
  2. D - Drugs
  3. DILTIAZEM hydrochloride, 25mg, powder, vial
Public Pricelist

DILTIAZEM hydrochloride, 25mg, powder, vial

https://unicat.msf.org/cat/product/53862
STD DINJDILT2V-

Valid Article

Former Code(s): -X DINJZFR0195 DINJZBE0041
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
12.1 - Antianginal medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
12.2 - Antiarrhythmic medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
12.3 - Antihypertensive medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
C08DB01
Anatomical Therapeutic Chemical Classification according to WHOCC
S
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://www.unicat.msf.org/web/image/product.template/569594/image_1920?unique=7806352

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

DILTIAZEM hydrochloride

Therapeutic Action

Calcium-channel blocker, antiarrhythmic

Indications

  • Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias (SVT)
  • Temporary control of rapid ventricular rate in atrial fibrillation or flutter

Verapamil is preferred for the same indications

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Reconstitute the powder vial with water for injection.

Must be given as direct IV injection or IV infusion in 5% dextrose or 0.9% NaCl.

Posology (Adults):

  • Initial dose: 0.25 mg/kg (average adult dose:15-20 mg) by direct IV over 2 minutes
  • If response inadequate after 15 minutes: 0.35 mg/kg (average adult dose: 20-25 mg) by direct IV over 2 minutes
  • Maintenance: continuous IV infusion 5 mg/hr, increase as needed up to 15 mg/hr for up to 24 hours

Administer only in hospital settings with monitoring and cardiorespiratory resuscitation equipment available for immediate use.

During administration, continuous ECG monitoring is necessary due to the risk of fatal arrhythmias.

Verapamil or adenosine may be used as alternative in case of supply constraints.

Contact your OC anaesthetist advisor for more details.

Precautions for Use

Do not administer in children.

Contraindicated in patients with:

  • Cardiogenic shock
  • Decompensated heart failure or severe left ventricular dysfunction
  • Symptomatic hypotension (SBP < 90mmHg)
  • Sick sinus syndrome (unless permanent pacemaker in place)
  • Wide-complex tachycardia
  • 2nd/3rd degree AV block (unless permanent pacemaker in place)
  • Atrial flutter/fibrillation combined with Wolff-Parkinson-White syndrome

Do not combine with betablocker due to risk of severe bradycardia or heart block.

Storage

  • Below 25ºC
  • After opening/reconstitution/dilution, use the product immediately.